Last reviewed · How we verify
NCT06186024
A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX
NA trial testing Bridge in Brain Diseases in 36 participants. Status unknown.
30 July 2024
Quick facts
| Lead sponsor | MicroPort NeuroTech Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 27 September 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bridge
Conditions studied
- Brain Diseases — all drugs for Brain Diseases →
- Vertebral Artery Thrombosis — all drugs for Vertebral Artery Thrombosis →
- Vertebral Artery Stenosis — all drugs for Vertebral Artery Stenosis →
Sponsor
MicroPort NeuroTech Co., Ltd.
Who can join
Adults 18 to 80, any sex, with Brain Diseases or Vertebral Artery Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aprospective, multicentre, single-arm clinical trial in which approximately 36 subjects would be enrolled using the Bridge 4.5 mm and 5.0 mm stent in accordance with the inclusion and exclusion criteria in this protocol. The success rate of immediate post-procedure stent target lesion treatment was recorded for all subjects, and the incidence of in-stent restenosis (≥50% stenosis) was assessed by DSA imaging follow-up at 6 months (±30 days) post-procedure. The subjects were also followed up at 30 days (±7 days), 6 months (±30 days), and 12 months (±60 days) after stent implantation to assess safety events during the follow-up period. .
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06186024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Diseases
Currently open trials in the same condition.
- NCT07185022 — Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion · NA · recruiting
- NCT07305948 — Evaluation of a New MRI Technique to Reduce Breathing-Related Artifacts in Brain Imaging · recruiting
- NCT07288385 — Investigating the Feasibility of Combining Virtual Reality and Bilateral Transcranial Direct Stimulation to Improve Uppe · NA · recruiting
- NCT07324330 — Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity · NA · recruiting
- NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
Other MicroPort NeuroTech Co., Ltd. trials
Trials by the same sponsor.
- NCT06925971 — A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atheroscleroti · Phase 3 · not yet recruiting
- NCT06843616 — A PILOT TRIAL of a DISPOSABLE INTRACEREBRAL ASPIRATION ENDOSCOPE for the TREATMENT of INTRACEREBRAL HEMATOMA（FAST-HET） · NA · recruiting
- NCT07314047 — The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation · NA · recruiting
- NCT06683118 — Registration Trial of the Drug-coated Balloon for the Symptomatic Cerebral Atherosclerotic Stenosis · NA · enrolling by invitation
- NCT06466564 — Bioabsorbable/Nufairy Coil Application Trial in China · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06186024 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MicroPort NeuroTech Co., Ltd.
- Last refreshed: 29 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06186024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing